WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Bayer

The Bayer GroupBayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,900 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion.

www.bayer.com.

Bayer RSS Channel

Filters
List of articles in category Bayer
Title Published Date
Rivaroxaban Significantly Reduces Risk of Stroke with Comparable Safety versus Warfarin 15 November 2010
Bayer raises its brand profile 08 November 2010
Phase III ROCKET AF Study of Rivaroxaban meets its primary efficacy endpoint with Comparable Safety vs. Warfarin 02 November 2010
Bayer lifts sales and earnings again 29 October 2010
21-Year Long-term Follow-up Study Demonstrates Significant Survival Advantage with Betaferon Treatment 18 October 2010
Bayer's Xarelto® Recognised with 2010 International Prix Galien Award 07 October 2010
Bayer's Rivaroxaban Successfully Meets Primary Efficacy Outcome 01 September 2010
Bayer increases sales and earnings in the second quarter 30 July 2010
Bayer Schering Pharma enters strategic partnership with Hospital in China 19 July 2010
Bayer Schering Pharma and OncoMed Pharmaceuticals Enter Strategic Alliance 18 June 2010
Trial of Nexavar® in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint 14 June 2010
Bayer Schering Pharma Enhances U.S. Research Strategy with New Innovation Center 18 May 2010
Bayer receives approval for its new oral contraceptive in the U.S. 17 May 2010
Bayer Schering Pharma Initiates Phase III Trial of Regorafenib 10 May 2010
Bayer Schering Pharma Initiates Phase III Trial of Regorafenib (BAY 73-4506) 10 May 2010
Bayer Schering Pharma and EndoCeutics Enter into a Global Agreement 06 May 2010
Bayer achieves strong gains in sales and earnings 30 April 2010
Bayer HealthCare Marks 2010 World Hemophilia Day with EUR 250,000 Contribution 19 April 2010
Bayer to Discontinue Phase II Clinical Trial for Long-Acting Recombinant Factor VIII 26 January 2010
Bayer to discontinue the LIPLONG study 26 January 2010
  • Start
  • Prev
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next
  • End

Business & Industry

  • Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
  • Bayer transforms pharma business through breakthrough innovation in healthcare
  • Valneva in advanced discussions with European Commission to supply up to 60 million doses of inactivated, adjuvanted COVID-19 vaccine candidate
  • An in vitro study shows Pfizer-BioNTech COVID-19 vaccine elicits antibodies that neutralize SARS-CoV-2 with a mutation associated with rapid transmission
  • European Commission authorizes COVID-19 vaccine Moderna in Europe

Research & Development

  • New England Journal of Medicine publishes COVID-19 treatment trial results
  • Scientists identify 'immune cop' that detects SARS-CoV-2
  • New findings help explain how COVID-19 overpowers the immune system
  • New virtual screening strategy identifies existing drug that inhibits COVID-19 virus
  • Sustained cellular immune dysregulation in individuals recovering from COVID-19
  • How SARS-CoV-2 interacts with cells
  • Neutralizing antibodies protect against severe COVID-19

Conferences & Events

  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production
  • Wearable Injectors and Connected Devices Conference 2020

Regulatory Affairs

  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  • FDA takes key action in fight against COVID-19 by issuing Emergency Use Authorization for first COVID-19 vaccine
  • EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2
  1. You are here:  
  2. Home
  3. Bayer
  4. Bayer transforms pharma business through breakthrough innovation in healthcare

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.